Astellas closes OSI acquisition following successful tender
This article was originally published in Scrip
Astellas has now completed its $4.0 billion acquisition of OSI Pharmaceuticals through a short-form merger, after it raising its ownership of the US oncology firm to more than 90% in an extended tender offer.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.